KYORIN Holdings, Inc.
JPX: 4569.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Yutaka Ogihara
- Employees
- 2,042
- Headquarters
- Tokyo, Japan
- IPO year
- 2001
- Market cap
- ¥89.1B
- Website
- https://www.kyorin-gr.co.jp
Loading 4569…
Loading profile data…Frequently asked questions about 4569
What does KYORIN Holdings, Inc. (4569.T) do?
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolo...
Where does 4569.T trade?
KYORIN Holdings, Inc. (4569.T) trades on the Tokyo Stock Exchange.
What sector is 4569.T in?
KYORIN Holdings, Inc. (4569.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of KYORIN Holdings, Inc.?
Yutaka Ogihara is the chief executive officer of KYORIN Holdings, Inc. (4569.T).
Where is KYORIN Holdings, Inc. headquartered?
KYORIN Holdings, Inc. is headquartered in Japan.
Does 4569.T pay a dividend?
Yes — KYORIN Holdings, Inc. (4569.T) paid a trailing twelve-month dividend of JPY 57.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4569.T go public?
KYORIN Holdings, Inc. (4569.T) completed its initial public offering in 2001.